U.S. Food and Drug Administration granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread to other parts of the body. Patients must have received at least two prior therapies before taking Trodelvy.
source https://www.pharmatutor.org/pharma-news/2020/fda-approves-new-therapy-for-triple-negative-breast-cancer-that-has-spread-not-responded-to-other-treatments
No comments:
Post a Comment